231 related articles for article (PubMed ID: 27226593)
41. Arachidonic acid-induced carbon-centered radicals and phospholipid peroxidation in cyclo-oxygenase-2-transfected PC12 cells.
Jiang J; Borisenko GG; Osipov A; Martin I; Chen R; Shvedova AA; Sorokin A; Tyurina YY; Potapovich A; Tyurin VA; Graham SH; Kagan VE
J Neurochem; 2004 Sep; 90(5):1036-49. PubMed ID: 15312159
[TBL] [Abstract][Full Text] [Related]
42. Interactions of 2-O-arachidonylglycerol ether and ibuprofen with the allosteric and catalytic subunits of human COX-2.
Dong L; Zou H; Yuan C; Hong YH; Uhlson CL; Murphy RC; Smith WL
J Lipid Res; 2016 Jun; 57(6):1043-50. PubMed ID: 27059979
[TBL] [Abstract][Full Text] [Related]
43. Effects of non-steroidal anti-inflammatory drugs on polymorphonuclear leukocyte functions in vitro: focus on fenamates.
Kankaanranta H; Moilanen E; Vapaatalo H
Naunyn Schmiedebergs Arch Pharmacol; 1994 Dec; 350(6):685-91. PubMed ID: 7708126
[TBL] [Abstract][Full Text] [Related]
44. Synthesis of new ibuprofen derivatives with their in silico and in vitro cyclooxygenase-2 inhibitions.
Gundogdu-Hizliates C; Alyuruk H; Gocmenturk M; Ergun Y; Cavas L
Bioorg Chem; 2014 Feb; 52():8-15. PubMed ID: 24270352
[TBL] [Abstract][Full Text] [Related]
45. Identification of the two-phase mechanism of arachidonic acid regulating inflammatory prostaglandin E2 biosynthesis by targeting COX-2 and mPGES-1.
Akasaka H; Ruan KH
Arch Biochem Biophys; 2016 Aug; 603():29-37. PubMed ID: 27177970
[TBL] [Abstract][Full Text] [Related]
46. Identification of Tyr504 as an alternative tyrosyl radical site in human prostaglandin H synthase-2.
Rogge CE; Liu W; Wu G; Wang LH; Kulmacz RJ; Tsai AL
Biochemistry; 2004 Feb; 43(6):1560-8. PubMed ID: 14769032
[TBL] [Abstract][Full Text] [Related]
47. Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors.
Ghodsi R; Zarghi A; Daraei B; Hedayati M
Bioorg Med Chem; 2010 Feb; 18(3):1029-33. PubMed ID: 20061161
[TBL] [Abstract][Full Text] [Related]
48. Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation.
Hermanson DJ; Gamble-George JC; Marnett LJ; Patel S
Trends Pharmacol Sci; 2014 Jul; 35(7):358-67. PubMed ID: 24845457
[TBL] [Abstract][Full Text] [Related]
49. Fenamates and the potent inhibition of human liver phenol sulphotransferase.
Vietri M; De Santi C; Pietrabissa A; Mosca F; Pacifici GM
Xenobiotica; 2000 Feb; 30(2):111-6. PubMed ID: 10718119
[TBL] [Abstract][Full Text] [Related]
50. Molecular Docking and
Shah K; Mujwar S; Gupta JK; Shrivastava SK; Mishra P
Assay Drug Dev Technol; 2019 Aug; 17(6):285-291. PubMed ID: 31532713
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.
Gierse J; Nickols M; Leahy K; Warner J; Zhang Y; Cortes-Burgos L; Carter J; Seibert K; Masferrer J
Eur J Pharmacol; 2008 Jun; 588(1):93-8. PubMed ID: 18457826
[TBL] [Abstract][Full Text] [Related]
52. Differential binding mode of diverse cyclooxygenase inhibitors.
Llorens O; Perez JJ; Palomer A; Mauleon D
J Mol Graph Model; 2002 Mar; 20(5):359-71. PubMed ID: 11885959
[TBL] [Abstract][Full Text] [Related]
53. Inhibitor-induced changes in the intrinsic fluorescence of human cyclooxygenase-2.
Houtzager V; Ouellet M; Falgueyret JP; Passmore LA; Bayly C; Percival MD
Biochemistry; 1996 Aug; 35(33):10974-84. PubMed ID: 8718891
[TBL] [Abstract][Full Text] [Related]
54. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs.
Reddy RN; Mutyala R; Aparoy P; Reddanna P; Reddy MR
Curr Pharm Des; 2007; 13(34):3505-17. PubMed ID: 18220787
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.
Zarghi A; Ghodsi R
Bioorg Med Chem; 2010 Aug; 18(16):5855-60. PubMed ID: 20650641
[TBL] [Abstract][Full Text] [Related]
56. Mutual synergy between catalase and peroxidase activities of the bifunctional enzyme KatG is facilitated by electron hole-hopping within the enzyme.
Njuma OJ; Davis I; Ndontsa EN; Krewall JR; Liu A; Goodwin DC
J Biol Chem; 2017 Nov; 292(45):18408-18421. PubMed ID: 28972181
[TBL] [Abstract][Full Text] [Related]
57. New selective cyclooxygenase-2 inhibitors from cyclocoumarol: Synthesis, characterization, biological evaluation and molecular modeling.
Rayar AM; Lagarde N; Martin F; Blanchard F; Liagre B; Ferroud C; Zagury JF; Montes M; Sylla-Iyarreta VeitÃa M
Eur J Med Chem; 2018 Feb; 146():577-587. PubMed ID: 29407982
[TBL] [Abstract][Full Text] [Related]
58. Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
Gouveia-Figueira S; Karlsson J; Deplano A; Hashemian S; Svensson M; Fredriksson Sundbom M; Congiu C; Onnis V; Fowler CJ
PLoS One; 2015; 10(9):e0139212. PubMed ID: 26406890
[TBL] [Abstract][Full Text] [Related]
59. Pulsed Dipolar Spectroscopy Reveals That Tyrosyl Radicals Are Generated in Both Monomers of the Cyclooxygenase-2 Dimer.
Orlando BJ; Borbat PP; Georgieva ER; Freed JH; Malkowski MG
Biochemistry; 2015 Dec; 54(50):7309-12. PubMed ID: 26636181
[TBL] [Abstract][Full Text] [Related]
60. Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics.
Konkle ME; Blobaum AL; Moth CW; Prusakiewicz JJ; Xu S; Ghebreselasie K; Akingbade D; Jacobs AT; Rouzer CA; Lybrand TP; Marnett LJ
Biochemistry; 2016 Jan; 55(2):348-59. PubMed ID: 26704937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
